Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:33 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
NCT03860844 · Sanofi · PHASE2 · terminated · last registry update 2025-09-09 · Childhood acute lymphoblastic leukemia · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study was prematurely stopped due to sponsor decision (stage 2 efficacy criteria not met); not due to safety concerns.” | – | Registry record, Sanofi |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD38 in childhood acute lymphoblastic leukemia within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-07-18Phase 3 first posted: Children's Oncology Group, Bortezomib + Calaspargase Pegol (NCT07072585)
- 2025-03-06Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Randomization + Blinatumomab + chemotherapy + Randomization + Isatuximab + Standard frontline T-ALL chemotherapy backbone (NCT06860269)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision